Peter Smith, Remix Therapeutics CEO
May 17, 2022 06:45 AM EDTUpdated 08:24 AM
Financing

Fol­low­ing po­ten­tial bil­lion-dol­lar J&J deal, RNA pro­cess­ing biotech Remix re­turns with fresh fi­nanc­ing

Lei Lei Wu

News Reporter

A few months ago, Remix Ther­a­peu­tics penned a deal with John­son & John­son that could end up be­ing worth more than $1 bil­lion dol­lars down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times